Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript

Lauren Nowak

All right, seems like everybody has managed to make their way. So I just wanted to say good morning, and thank you for joining Cynata Therapeutics Investor Webinar for the September 2025 quarter. Presenting this morning will be CEO and Managing Director, Dr. Kilian Kelly; and Chief Business Officer, Dr. Mathias Kroll. Both will provide us an update on Cynata’s clinical programs, corporate developments and financial position, followed by a Q&A session. [Operator Instructions]

And as a reminder, this webinar is being recorded and will be available on the company website in coming days. I’ll now hand over to Kilian to formally welcome you all and commence the presentation.

Kilian Kelly
MD, CEO & Director

Thanks very much, Lauren, and thanks to everybody for joining us this morning. So as we usually do with these webinars, we’ll go through a relatively brief presentation with some key points of our progress over the last quarter and the outlook ahead. And then we’ll leave time at the end for questions. As Lauren said, you can submit questions through the webinar system, and we will get to those after we conclude the presentation.

So this really is an enormously exciting time for the company. It is no exaggeration at all to say it’s the most important chapter in the company’s history. And that’s because we have 2 major clinical trial readouts within the next 6 to 9 months. Obviously, we’ll cover a bit more about those in a moment. Importantly, both of those trials are designed to show efficacy of our products in diseases with unmet needs